Integrity Alliance LLC. Grows Position in Pfizer Inc. $PFE

Key Points

• Integrity Alliance LLC increased its holdings in Pfizer Inc. by 144.6% during the first quarter, acquiring an additional 73,788 shares, bringing its total shares to 124,827 worth approximately $3.16 million.
• Pfizer reported a quarterly earnings per share of $0.78, surpassing analyst estimates and showing a 10.3% year-over-year revenue growth of about $14.65 billion.
• The company's recently declared quarterly dividend is $0.43 per share, which translates to an annualized dividend yield of 7.0% and a payout ratio of 91.49%.

Integrity Alliance LLC. raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 144.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 124,827 shares of the biopharmaceutical company's stock after acquiring an additional 73,788 shares during the quarter. Integrity Alliance LLC.'s holdings in Pfizer were worth $3,163,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. Gould Capital LLC increased its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter worth about $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PFE shares. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.95 during trading on Friday, hitting $23.91. 81,158,118 shares of the company's stock were exchanged, compared to its average volume of 34,996,196. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The business's 50-day simple moving average is $24.79 and its 200 day simple moving average is $24.30. The company has a market cap of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.